ADC Therapeutics SAvsAmgen

ADCT and AMGN stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$442.71

Value $239B

-3.50%
AMGN's page

ADC Therapeutics SA (ADCT) has a market value of $167M and Amgen (AMGN) $239B. Over the last year, with dividends, ADCT moved -66.8% and AMGN +32.9%. Dividend yield: ADCT none, AMGN 2.25%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ADCT$167M

    AMGN$239B

    AMGN is 1,429 times ADCT

  • Revenue, 12 months

    ADCT$85M

    AMGN$38.9B

    AMGN is 458 times ADCT

  • Net income, 12 months

    ADCT-$81M

    AMGN$9.4B

  • Operating margin

    ADCT-97.7%

    AMGN32.4%

    130.1 points apart

  • ROIC

    ADCT–

    AMGN16.2%

  • P/E

    ADCT–

    AMGN25.4

  • Dividend yield

    ADCT0.0%

    AMGN2.3%

    2.3 points apart

  • 5-year return

    ADCT-94.7%

    AMGN+148.8%

    243.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ADCT-94.7%

AMGN+148.8%

010020020222023202420252026
Returns by period
PeriodADCTWith dividendsAMGNWith dividends
1 year since November 17, 2025-66.8%Price -66.8%+32.9%Price +29.3%
3 years since November 17, 2023+87.5%+23.3% a yearPrice +87.5%+80.7%+21.8% a yearPrice +66.5%
5 years since November 17, 2021-94.7%-44.5% a yearPrice -94.7%+148.8%+20.0% a yearPrice +114.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ADCTADC Therapeutics SAAMGNAmgen

Valuation

ADCTAMGN
Valuation
Price$1.31$442.71
Market value$167M$239B
Enterprise value (EV)–$279B
P/E–25.4
P/E, 5-year median–23.0
P/B–16.6
EV/EBIT–22.2
Free cash flow yield–4.0%

Results and growth

ADCTAMGN
Results and growth
Revenue, 12 months$85M$38.9B
Net income, 12 months-$81M$9.4B
Free cash flow, 12 months-$101M$9.6B
Earnings per share, 12 months-$0.46$17.25
Revenue growth, year on year14.9%10.0%
Revenue growth a year, past–+7.6%over 5 years
EPS growth a year, past–+2.9%over 5 years

Margins and returns on capital

ADCTAMGN
Margins and returns on capital
Gross margin92.9%70.9%
Operating margin-97.7%32.4%
Net margin-95.7%24.1%
ROIC–16.2%
ROE–87.8%

Balance sheet

ADCTAMGN
Balance sheet
Cash$189M$13.2B
Total debt–$54.0B
Net debt / EBITDA–2.3
Interest cover-1.6×4.8×

Dividends and buybacks

ADCTAMGN
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$9.94
Dividend growth a year, past–+8.1%over 5 years
Buyback yield––
Shareholder yield–2.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ADCT or AMGN

Didn't find what you were looking for?

Ask us
Which is bigger, ADC Therapeutics SA or Amgen?

By market value, Amgen ($239B) is about 1,428.5 times ADC Therapeutics SA ($167M), at today's prices.

How did ADCT and AMGN stock do over the last 5 years?

Since November 17, 2021, ADCT's price moved -94.7% and AMGN's +114.7%. With dividends: ADCT -94.7% (-44.5% a year), AMGN +148.8% (+20.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, ADCT or AMGN?

The dividend yield at today's price is none for ADC Therapeutics SA and 2.25% for Amgen. Over the last twelve months they paid – and $9.94 per share.

Which has the higher profit margins, ADC Therapeutics SA or Amgen?

Over the last twelve months, the net margin was -95.7% for ADC Therapeutics SA and 24.1% for Amgen, and the operating margin -97.7% and 32.4%. Revenue was $85M and $38.9B.

Which is the better investment, ADC Therapeutics SA or Amgen?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.